STAT+: A Sellas immunotherapy study, long delayed, will end in failure
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Sellas Life Sciences Group is a blowup waiting to happen. My prediction: Sellas’…
ImpactMinor 11/100
Why it mattersRule-based estimate: event keywords (+4), soft/evergreen signals; trust 8/10.
RegionsGlobal
Published1 d ago (Thu, 17 Sep 2026 10:30:00 GMT)
RetrievedThu, 17 Sep 2026 11:30:17 GMT via rss
ClassifiedThu, 17 Sep 2026 11:30:25 GMT by heuristic
AuthorAdam Feuerstein